FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency initiates advance notice of proposed rulemaking to determine whether an active drug ingredient can be marketed both Rx and OTC for the same indication.
You may also be interested in...
FDA Commissioner Nomination Hearing Scheduled By Senate Health Committee
Nomination of FDA Acting Commissioner von Eschenbach to the post will be reviewed Aug. 1, although a vote is not anticipated.
FDA Commissioner Nomination Hearing Scheduled By Senate Health Committee
Nomination of FDA Acting Commissioner von Eschenbach to the post will be reviewed Aug. 1, although a vote is not anticipated.
“New” Plan B Emails Say FDA’s “Novel” Concerns Were Not Novel – Waxman
FDA had begun considering the legality of marketing the emergency contraceptive over-the-counter for women age 16 and older and Rx for those under 16 as early as 2004, documents suggest.